Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NewAmsterdam Pharma Company N.V. (NAMS)
USD33.56
+0.28 (+0.84%)
NL NASDAQ Healthcare Biotechnology
Address
Gooimeer 2-35 1411 DC
Naarden, NH, NL
Naarden, NH, NL
CEO
Michael Davidson
Website
newamsterdampharma.com
IPO
2021-02-09
CIK 1936258 ISIN NL00150012L7
Also trades on
NASDAQ Capital Market · NAMS (USD)
NASDAQ Capital Market · NAMSW (USD)
Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD33.56
+0.28 (+0.84%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.08
Float Shares
71.47M
Free Float %
62.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.22% | +19.82% | +13.90% | +13.57% | +3.34% | +12.86% | +105.98% | +204.54% | +302.34% | +273.07% | +273.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
33.56
Low
37.00
+10.3%
Consensus
46.00
+37.1%
Median
46.00
+37.1%
High
55.00
+63.9%
DCF (Unlevered)
3.47
-89.7%
DCF (Levered)
2.75
-91.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 11 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
45.00
+34.1%
|
| Last Year | 6 |
46.83
+39.5%
|
| All Time | 11 |
44.36
+32.2%
|
Quality scores
Altman Z-Score
38.70
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-50.6% Q1'26: +2.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+31.6% ★ Q1'26: -17.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,113.1% Q1'26: -1,008.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,077.8% Q1'26: -1,921.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-511.8% Q1'26: -801.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+21.2% Q1'26: +4.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 8 EPS Ana. |
Dec 2027 9 Rev. Ana. 8 EPS Ana. |
Dec 2028 3 Rev. Ana. 7 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
102.69M
est: 113.04M (-9.2%)
|
14.09M
est: 14.38M (-2.0%)
|
45.56M
est: 33.77M (+34.9%)
|
22.50M
est: 26.99M (-16.6%)
|
29.28M
28.56M – 30.71M
+8.5% YoY
|
171.15M
21.47M – 535.76M
+484.6% YoY
|
422.68M
106.07M – 1.27B
+147.0% YoY
|
796.40M
199.85M – 2.39B
+88.4% YoY
|
1.14B
286.76M – 3.42B
+43.5% YoY
|
| EBITDA |
-22.34M
est: -4.92M (-354.2%)
|
-176.86M
est: -625.7K (-28,166.7%)
|
-241.49M
est: -14.98M (-1,512.3%)
|
-242.33M
est: -11.97M (-1,924.4%)
|
-12.99M
-13.62M – -12.67M
-8.5% YoY
|
-75.91M
-237.61M – -9.52M
-484.6% YoY
|
-187.46M
-561.49M – -47.04M
-147.0% YoY
|
-353.21M
-1.06B – -88.63M
-88.4% YoY
|
-506.81M
-1.52B – -127.18M
-43.5% YoY
|
| EBIT |
-22.35M
est: -4.92M (-354.2%)
|
-176.91M
est: -625.9K (-28,163.2%)
|
-241.60M
est: -14.98M (-1,513.0%)
|
-242.55M
est: -11.97M (-1,926.2%)
|
-12.99M
-13.62M – -12.67M
-8.5% YoY
|
-75.91M
-237.62M – -9.52M
-484.6% YoY
|
-187.47M
-561.51M – -47.04M
-147.0% YoY
|
-353.22M
-1.06B – -88.64M
-88.4% YoY
|
-506.83M
-1.52B – -127.18M
-43.5% YoY
|
| Net Income |
-22.63M
est: 16.88M (-234.1%)
|
-176.94M
est: -202.81M (+12.8%)
|
-241.60M
est: -232.39M (-4.0%)
|
-203.82M
est: -175.93M (-15.9%)
|
-209.70M
-246.78M – -179.58M
-19.2% YoY
|
-162.39M
-456.12M – 333.26M
+22.6% YoY
|
-32.31M
-116.12M – -847.3K
+80.1% YoY
|
177.78M
4.66M – 638.89M
+650.2% YoY
|
366.71M
9.62M – 1.32B
+106.3% YoY
|
| SGA |
19.51M
est: 144.85M (-86.5%)
|
37.63M
est: 18.43M (+104.2%)
|
70.45M
est: 68.43M (+3.0%)
|
106.30M
est: 54.68M (+94.4%)
|
59.32M
57.87M – 62.22M
+8.5% YoY
|
346.77M
43.50M – 1.09B
+484.6% YoY
|
856.40M
214.90M – 2.57B
+147.0% YoY
|
1.61B
404.92M – 4.83B
+88.4% YoY
|
2.32B
581.01M – 6.93B
+43.5% YoY
|
| EPS |
-1.19
est: 0.18 (-765.1%)
|
-2.15
est: -2.15 (0.0%)
|
-2.56
est: -2.03 (-26.0%)
|
-1.75
est: -1.54 (-13.8%)
|
-1.83
-2.16 – -1.57
-19.2% YoY
|
-1.42
-3.99 – 2.91
+22.6% YoY
|
-0.28
-1.02 – -0.01
+80.1% YoY
|
1.55
0.04 – 5.58
+650.2% YoY
|
3.21
0.08 – 11.52
+106.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-148.24M
OE per share TTM
-1.29
Owner's Yield
-3.72%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
144.14M
Insider transactions (90d)
0
Beneficial owners (>5%)
45
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | James N. Topper | 9.80M | 12.00% | — | 9.80M | — | 11.00 | IN | — | 2022-12-02 | ↗ |
| 2 | Patrick J. Heron | 9.80M | 12.00% | — | 9.80M | — | 9.80M | IN | — | 2022-12-02 | ↗ |
| 3 | Coöperatief U.A. | 6.64M | 8.10% | — | 6.64M | — | 6.64M | OO | — | 2023-07-07 | ↗ |
| 4 | David C. Ott | 6.52M | 7.98% | — | 6.52M | — | 6.52M | IN | Cayman Islands | 2023-06-20 | ↗ |
| 5 | O. Andreas Halvorsen | 6.52M | 7.98% | — | 6.52M | — | 6.52M | IN | Cayman Islands | 2023-06-20 | ↗ |
| 6 | Rose S. Shabet | 6.52M | 7.98% | — | 6.52M | — | 6.52M | IN | Cayman Islands | 2023-06-20 | ↗ |
| 7 | Viking Global Investors LP | 6.52M | 7.98% | — | 6.52M | — | 6.52M | PN | Cayman Islands | 2023-06-20 | ↗ |
| 8 | Viking Global Opportunities Parent GP LLC | 6.52M | 7.98% | — | 6.52M | — | 6.52M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 9 | B.V. | 5.33M | 6.50% | — | 5.33M | — | 5.33M | OO | — | 2023-07-07 | ↗ |
| 10 | NewAmsterdam Pharma | 5.33M | 6.50% | — | 5.33M | — | 5.33M | OO | — | 2023-07-07 | ↗ |
| 11 | Morningside Venture Investments Ltd | 5.07M | 6.21% | — | 5.07M | — | 5.07M | CO | British Virgin Islands | 2022-12-02 | ↗ |
| 12 | AMGEN INC. | 4.91M | 6.00% | — | 4.91M | — | — | CO | Netherlands | 2022-12-02 | ↗ |
| 13 | AMGEN SINGAPORE MANUFACTURING PTE. LTD. | 4.91M | 6.00% | — | 4.91M | — | 4.91M | CO | Netherlands | 2022-12-02 | ↗ |
| 14 | AMGEN TECHNOLOGY, LIMITED | 4.91M | 6.00% | — | 4.91M | — | 4.91M | CO | Netherlands | 2022-12-02 | ↗ |
| 15 | ONYX PHARMACEUTICALS, INC. | 4.91M | 6.00% | — | 4.91M | — | — | CO | Netherlands | 2022-12-02 | ↗ |
| 16 | SAGA INVESTMENTS COÖPERATIEF U.A. | 4.91M | 6.00% | — | 4.91M | — | 4.91M | CO | Netherlands | 2022-12-02 | ↗ |
| 17 | Viking Global Opportunities GP LLC | 4.37M | 5.35% | — | 4.37M | — | 4.37M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 18 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 4.37M | 5.35% | — | 4.37M | — | 4.37M | PN | Cayman Islands | 2023-06-20 | ↗ |
| 19 | Viking Global Opportunities Portfolio GP LLC | 4.37M | 5.35% | — | 4.37M | — | 4.37M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 20 | Peter Kolchinsky | 4.33M | 5.29% | — | 4.33M | — | — | HC, IN | United States of America | 2022-12-02 | ↗ |
| 21 | RA Capital Healthcare Fund, L.P. | 4.33M | 5.29% | — | 4.33M | — | — | PN | Delaware | 2022-12-02 | ↗ |
| 22 | RA Capital Management, L.P. | 4.33M | 5.29% | — | 4.33M | — | — | IA, PN | Delaware | 2022-12-02 | ↗ |
| 23 | Rajeev Shah | 4.33M | 5.29% | — | 4.33M | — | — | HC, IN | United States of America | 2022-12-02 | ↗ |
| 24 | BCLS Fund III Investments, LP | 4.00M | 4.90% | — | 4.00M | — | 4.00M | PN | — | 2022-12-02 | ↗ |
| 25 | BCLS II Investco, LP | 4.00M | 4.90% | — | 4.00M | — | 4.00M | PN | — | 2022-12-02 | ↗ |
| 26 | Frazier Lifesciences Sponsor LLC | 3.97M | 4.90% | — | 3.97M | — | 3.97M | OO | — | 2022-12-02 | ↗ |
| 27 | FHMLS X, L.L.C. | 3.33M | 4.09% | — | 3.33M | — | 3.33M | PN | — | 2022-12-02 | ↗ |
| 28 | FHMLS X, L.P. | 3.33M | 4.09% | — | 3.33M | — | 3.33M | PN | — | 2022-12-02 | ↗ |
| 29 | Frazier Life Sciences X, L.P. | 3.33M | 4.09% | — | 3.33M | — | 3.33M | PN | — | 2022-12-02 | ↗ |
| 30 | Viking Global Opportunities Drawdown (Aggregator) LP | 2.15M | 2.63% | — | 2.15M | — | 2.15M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 31 | Viking Global Opportunities Drawdown GP LLC | 2.15M | 2.63% | — | 2.15M | — | 2.15M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 32 | Viking Global Opportunities Drawdown Portfolio GP LLC | 2.15M | 2.63% | — | 2.15M | — | 2.15M | OO | Cayman Islands | 2023-06-20 | ↗ |
| 33 | Albert Cha | 2.00M | 2.50% | — | 2.00M | — | 2.00M | IN | — | 2022-12-02 | ↗ |
| 34 | James Brush | 2.00M | 2.50% | — | 2.00M | — | 2.00M | IN | — | 2022-12-02 | ↗ |
| 35 | FHMLSP Overage, L.L.C. | 1.00M | 1.20% | — | 1.00M | — | 1.00M | OO | — | 2022-12-02 | ↗ |
| 36 | FHMLSP Overage, L.P. | 1.00M | 1.20% | — | 1.00M | — | 1.00M | PN | — | 2022-12-02 | ↗ |
| 37 | FHMLSP, L.L.C. | 1.00M | 1.20% | — | 1.00M | — | 1.00M | OO | — | 2022-12-02 | ↗ |
| 38 | FHMLSP, L.P. | 1.00M | 1.20% | — | 1.00M | — | 1.00M | PN | — | 2022-12-02 | ↗ |
| 39 | Frazier Life Sciences Overage Fund L.P. | 1.00M | 1.20% | — | 1.00M | — | 1.00M | PN | — | 2022-12-02 | ↗ |
| 40 | Dan Estes | 500.0K | 0.60% | — | 500.0K | — | 500.0K | IN | — | 2022-12-02 | ↗ |
| 41 | FHMLS XI, L.L.C. | 500.0K | 0.60% | — | 500.0K | — | 500.0K | OO | — | 2022-12-02 | ↗ |
| 42 | FHMLS XI, L.P. | 500.0K | 0.60% | — | 500.0K | — | 500.0K | PN | — | 2022-12-02 | ↗ |
| 43 | Frazier Life Sciences XI, L.P. | 500.0K | 0.60% | — | 500.0K | — | 500.0K | PN | — | 2022-12-02 | ↗ |
| 44 | Bain Capital Life Sciences Fund II, L.P. | 356.6K | 0.40% | — | 356.6K | — | 356.6K | PN | — | 2022-12-02 | ↗ |
| 45 | BCIP Life Sciences Associates, LP | 43.4K | 0.10% | — | 43.4K | — | 43.4K | PN | — | 2022-12-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-166 vs prev Q
New positions
5
Closed positions
163
Increased
15
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 16.94M +241.8K (+1.4%) | 594.39M +119.4M (+25.1%) | 14.24% -0.606 pp | 15.96% +1.732 pp | USD14.58 +140.6% | 13 qtrs — |
| 2 | CAPITAL WORLD INVESTORS | 9.98M +161.3K (+1.6%) | 350.24M +70.9M (+25.4%) | 8.39% -0.341 pp | 0.05% +0.010 pp | USD22.01 +59.4% | 5 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 9.55M -588.7K (-5.8%) | 335.02M +46.7M (+16.2%) | 8.03% -0.986 pp | 3.43% -0.121 pp | USD13.88 +152.7% | 13 qtrs — |
| 4 | FCPM III SERVICES B.V. | 9.20M -13.5K (-0.1%) | 322.70M +60.7M (+23.2%) | 7.73% -0.458 pp | 42.30% -10.060 pp | USD11.46 +206.1% | 9 qtrs — |
| 5 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 7.31M -3.4M (-31.8%) | 256.31M -48.5M (-15.9%) | 6.14% -3.387 pp | 19.63% -0.602 pp | USD11.44 +206.6% | 13 qtrs — |
| 6 | FMR LLC | 6.41M +877.7K (+15.9%) | 224.97M +67.5M (+42.9%) | 5.39% +0.469 pp | 0.01% +0.003 pp | USD26.64 +31.7% | 8 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 5.03M +1.0M (+25.2%) | 176.56M +62.2M (+54.4%) | 4.23% +0.656 pp | 0.03% +0.011 pp | USD26.69 +31.4% | 8 qtrs — |
| 8 | VIKING GLOBAL INVESTORS LP | 4.20M -2.3M (-35.1%) | 147.46M -36.7M (-19.9%) | 3.53% -2.223 pp | 0.39% -0.087 pp | USD10.96 +220.1% | 13 qtrs — |
| 9 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4.16M -101.9K (-2.4%) | 146.10M +24.8M (+20.4%) | 3.50% -0.293 pp | 1.87% +0.014 pp | USD23.41 +49.9% | 8 qtrs — |
| 10 | JENNISON ASSOCIATES LLC | 3.49M -709.3K (-16.9%) | 122.40M +3.0M (+2.5%) | 2.93% -0.800 pp | 0.07% +0.004 pp | USD25.67 +36.7% | 8 qtrs — |
| 11 | DUQUESNE FAMILY OFFICE LLC | 3.07M +1.1M (+59.6%) | 107.70M +53.0M (+96.9%) | 2.58% +0.870 pp | 2.40% +1.049 pp | USD28.37 +23.7% | 6 qtrs — |
| 12 | MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 2.87M +— (+0.0%) | 100.66M +19.1M (+23.3%) | 2.41% -0.139 pp | 12.06% +1.093 pp | USD11.20 +213.2% | 13 qtrs — |
| 13 | POLAR CAPITAL HOLDINGS PLC | 2.78M -135.4K (-4.7%) | 97.39M +14.6M (+17.6%) | 2.33% -0.255 pp | 0.38% -0.022 pp | USD21.41 +63.8% | 8 qtrs — |
| 14 | JANUS HENDERSON GROUP PLC | 2.34M +224.6K (+10.6%) | 82.30M +22.2M (+36.8%) | 1.97% +0.086 pp | 0.04% +0.009 pp | USD22.26 +57.6% | 10 qtrs — |
| 15 | CAPITAL INTERNATIONAL INVESTORS | 2.06M +— (+0.0%) | 72.35M +13.7M (+23.3%) | 1.73% -0.100 pp | 0.01% +0.002 pp | USD25.70 +36.5% | 5 qtrs — |
| 16 | MAVERICK CAPITAL LTD | 1.89M +389.5K (+25.9%) | 66.45M +23.7M (+55.3%) | 1.59% +0.254 pp | 0.71% +0.141 pp | USD23.22 +51.1% | 5 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 1.73M +845.1K (+96.0%) | 60.54M +35.5M (+141.7%) | 1.45% +0.668 pp | 0.01% +0.004 pp | USD28.72 +22.1% | 9 qtrs — |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.41M -1.2M (-45.4%) | 49.34M -23.9M (-32.7%) | 1.18% -1.108 pp | 0.07% -0.041 pp | USD17.58 +99.5% | 11 qtrs — |
| 19 | ALLIANCEBERNSTEIN L.P. | 1.30M -840.9K (-39.3%) | 45.63M -15.3M (-25.1%) | 1.09% -0.811 pp | 0.01% -0.005 pp | USD24.55 +42.9% | 5 qtrs — |
| 20 | CASTLE HOOK PARTNERS LP | 1.09M +1.1M (+100.0%) | 38.06M +38.1M (+100.0%) | 0.91% +0.912 pp | 0.16% +0.158 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 21 | CORMORANT ASSET MANAGEMENT, LP | 1.00M -1.2M (-54.0%) | 35.08M -26.8M (-43.3%) | 0.84% -1.093 pp | 1.62% -2.646 pp | USD21.97 +59.7% | 8 qtrs — |
| 22 | JPMORGAN CHASE & CO | 1,000.0K -302.5K (-23.2%) | 35.08M -2.0M (-5.3%) | 0.84% -0.317 pp | 0.00% +0.000 pp | USD19.82 +77.0% | 13 qtrs — |
| 23 | UBS GROUP AG | 899.4K +130.9K (+17.0%) | 31.55M +9.7M (+44.4%) | 0.76% +0.073 pp | 0.01% +0.002 pp | USD22.92 +53.1% | 11 qtrs — |
| 24 | FIRST TURN MANAGEMENT, LLC | 893.5K +176.5K (+24.6%) | 31.34M +11.0M (+53.7%) | 0.75% +0.114 pp | 3.58% +0.520 pp | USD23.73 +47.8% | 3 qtrs — |
| 25 | BLACKROCK, INC. | 849.8K +227.3K (+36.5%) | 29.81M +12.1M (+68.4%) | 0.71% +0.161 pp | 0.00% +0.000 pp | USD26.65 +31.6% | 6 qtrs — |
| 26 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 822.3K -15.1K (-1.8%) | 28.85M +5.0M (+21.1%) | 0.69% -0.053 pp | 0.43% +0.094 pp | USD24.40 +43.8% | 8 qtrs — |
| 27 | FRANKLIN RESOURCES INC | 769.1K +363.3K (+89.5%) | 26.98M +15.4M (+133.8%) | 0.65% +0.286 pp | 0.01% +0.004 pp | USD27.87 +25.9% | 4 qtrs — |
| 28 | WOODLINE PARTNERS LP | 751.3K -406.6K (-35.1%) | 26.35M -6.6M (-20.0%) | 0.63% -0.398 pp | 0.10% -0.053 pp | USD22.12 +58.6% | 7 qtrs — |
| 29 | PICTET ASSET MANAGEMENT HOLDING SA | 746.1K -546.0K (-42.3%) | 26.17M -10.6M (-28.8%) | 0.63% -0.522 pp | 0.03% -0.010 pp | USD20.48 +71.3% | 8 qtrs — |
| 30 | ABRDN PLC | 729.5K +67.5K (+10.2%) | 25.59M +6.8M (+35.9%) | 0.61% +0.025 pp | 0.04% +0.010 pp | USD20.86 +68.2% | 7 qtrs — |
| 31 | CITADEL ADVISORS LLC | 635.2K +428.8K (+207.7%) | 22.28M +16.4M (+279.5%) | 0.53% +0.350 pp | 0.00% +0.003 pp | USD30.75 +14.1% | 10 qtrs — |
| 32 | AMERICAN CENTURY COMPANIES INC | 603.4K -20.9K (-3.3%) | 21.17M +3.4M (+19.2%) | 0.51% -0.048 pp | 0.01% +0.002 pp | USD24.52 +43.1% | 5 qtrs — |
| 33 | DECHENG CAPITAL LLC | 592.1K -65.0K (-9.9%) | 20.77M +2.1M (+11.1%) | 0.50% -0.087 pp | 2.79% -0.466 pp | USD20.79 +68.7% | 7 qtrs — |
| 34 | ENSIGN PEAK ADVISORS, INC | 549.5K +549.5K (+100.0%) | 19.28M +19.3M (+100.0%) | 0.46% +0.462 pp | 0.03% +0.034 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 35 | MORGAN STANLEY | 532.8K -964.7K (-64.4%) | 18.69M -23.9M (-56.1%) | 0.45% -0.883 pp | 0.00% -0.002 pp | USD25.05 +40.0% | 12 qtrs — |
| 36 | ARTIA GLOBAL PARTNERS LP | 503.9K +309.1K (+158.6%) | 17.68M +12.1M (+219.0%) | 0.42% +0.250 pp | 2.82% +1.942 pp | USD31.95 +9.8% | 8 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 459.4K -12.7K (-2.7%) | 16.12M +2.7M (+20.0%) | 0.39% -0.034 pp | 0.00% +0.000 pp | USD20.80 +68.7% | 8 qtrs — |
| 38 | LOGOS GLOBAL MANAGEMENT LP | 450.0K +450.0K (+100.0%) | 15.79M +15.8M (+100.0%) | 0.38% +0.378 pp | 0.95% +0.954 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 39 | JANE STREET GROUP, LLC | 421.5K +421.5K (+100.0%) | 14.79M +14.8M (+100.0%) | 0.35% +0.354 pp | 0.00% +0.002 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 40 | EVERSEPT PARTNERS, LP | 420.8K -67.8K (-13.9%) | 14.76M +867.1K (+6.2%) | 0.35% -0.081 pp | 0.74% -0.214 pp | USD16.25 +115.9% | 12 qtrs — |
| 41 | HANDELSBANKEN FONDER AB | 415.8K +10.0K (+2.5%) | 14.59M +3.0M (+26.4%) | 0.35% -0.011 pp | 0.04% +0.007 pp | USD23.95 +46.5% | 5 qtrs — |
| 42 | BANK OF NEW YORK MELLON CORP | 391.8K +58.8K (+17.7%) | 13.75M +4.3M (+45.1%) | 0.33% +0.033 pp | 0.00% +0.001 pp | USD20.66 +69.8% | 3 qtrs — |
| 43 | SLATE PATH CAPITAL LP | 319.0K +— (+0.0%) | 11.19M +2.1M (+23.3%) | 0.27% -0.016 pp | 0.15% +0.011 pp | USD25.70 +36.5% | 5 qtrs — |
| 44 | ARROWMARK COLORADO HOLDINGS LLC | 298.1K -12.9K (-4.2%) | 10.46M +1.6M (+18.2%) | 0.25% -0.026 pp | 0.23% +0.066 pp | USD20.59 +70.4% | 8 qtrs — |
| 45 | FIRST TRUST ADVISORS LP | 279.7K +279.7K (+100.0%) | 9.81M +9.8M (+100.0%) | 0.24% +0.235 pp | 0.01% +0.007 pp | USD35.08 +0.0% | 4 qtrs — |
| 46 | AFFINITY ASSET ADVISORS, LLC | 275.0K +— (+0.0%) | 9.65M +1.8M (+23.3%) | 0.23% -0.013 pp | 0.55% -0.132 pp | USD18.00 +94.9% | 11 qtrs — |
| 47 | UBS ASSET MANAGEMENT AMERICAS INC | 265.2K +265.2K (+100.0%) | 9.30M +9.3M (+100.0%) | 0.22% +0.223 pp | 0.00% +0.002 pp | USD35.08 +0.0% | 7 qtrs — |
| 48 | MILLENNIUM MANAGEMENT LLC | 254.6K +254.6K (+100.0%) | 8.93M +8.9M (+100.0%) | 0.21% +0.214 pp | 0.00% +0.004 pp | USD35.08 +0.0% | 12 qtrs — |
| 49 | GILDER GAGNON HOWE & CO LLC | 248.5K +212.1K (+583.1%) | 8.72M +7.7M (+742.5%) | 0.21% +0.177 pp | 0.09% +0.082 pp | USD34.11 +2.8% | 8 qtrs — |
| 50 | NICHOLAS INVESTMENT PARTNERS, LP | 213.4K +35.9K (+20.2%) | 7.49M +2.4M (+48.3%) | 0.18% +0.022 pp | 0.55% +0.159 pp | USD23.95 +46.5% | 3 qtrs — |
| 51 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 201.3K +63.5K (+46.1%) | 7.06M +3.1M (+80.2%) | 0.17% +0.047 pp | 0.00% +0.000 pp | USD28.45 +23.3% | 5 qtrs — |
| 52 | LORD, ABBETT & CO. LLC | 200.6K +200.6K (+100.0%) | 7.04M +7.0M (+100.0%) | 0.17% +0.169 pp | 0.02% +0.022 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 53 | HEALTHINVEST PARTNERS AB | 197.0K +3.4K (+1.8%) | 6.91M +6.3M (+1,082.3%) | 0.17% -0.007 pp | 2.21% +0.038 pp | USD20.74 +69.1% | 8 qtrs — |
| 54 | LISANTI CAPITAL GROWTH, LLC | 179.4K +132.0K (+278.1%) | 6.29M +4.9M (+366.4%) | 0.15% +0.109 pp | 1.49% +1.161 pp | USD30.41 +15.4% | 6 qtrs — |
| 55 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 177.0K +177.0K (+100.0%) | 6.21M +6.2M (+100.0%) | 0.15% +0.149 pp | 0.01% +0.007 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 56 | VANGUARD GROUP INC | 173.0K +490.0 (+0.3%) | 6.07M +1.2M (+23.7%) | 0.15% -0.008 pp | 0.00% +0.000 pp | USD19.06 +84.1% | 7 qtrs — |
| 57 | KENNEDY CAPITAL MANAGEMENT LLC | 172.9K +26.2K (+17.9%) | 6.07M +1.9M (+45.4%) | 0.15% +0.015 pp | 0.13% +0.036 pp | USD28.63 +22.5% | 7 qtrs — |
| 58 | DCF ADVISERS, LLC | 160.6K -14.7K (-8.4%) | 5.63M +649.7K (+13.0%) | 0.14% -0.021 pp | 1.51% -0.090 pp | USD21.50 +63.2% | 6 qtrs — |
| 59 | AMERIPRISE FINANCIAL INC | 152.3K +6.9K (+4.8%) | 5.34M +1.2M (+29.2%) | 0.13% -0.001 pp | 0.00% +0.000 pp | USD19.91 +76.2% | 4 qtrs — |
| 60 | MOODY ALDRICH PARTNERS LLC | 143.5K +143.5K (+100.0%) | 5.04M +5.0M (+100.0%) | 0.12% +0.121 pp | 0.94% +0.940 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 61 | XTX TOPCO LTD | 137.5K +129.9K (+1,714.1%) | 4.82M +4.6M (+2,137.7%) | 0.12% +0.109 pp | 0.13% +0.116 pp | USD34.71 +1.1% | 2 qtrs — |
| 62 | DEUTSCHE BANK AG\ | 124.0K +55.5K (+81.2%) | 4.35M +2.4M (+123.5%) | 0.10% +0.043 pp | 0.00% +0.001 pp | USD26.97 +30.1% | 6 qtrs — |
| 63 | ADAR1 CAPITAL MANAGEMENT, LLC | 118.6K +4.3K (+3.7%) | 4.16M +908.9K (+27.9%) | 0.10% -0.002 pp | 0.31% +0.000 pp | USD18.89 +85.7% | 3 qtrs — |
| 64 | PRICE T ROWE ASSOCIATES INC /MD/ | 116.3K -22.1K (-16.0%) | 4.08M +144.0K (+3.7%) | 0.10% -0.025 pp | 0.00% +0.000 pp | USD28.44 +23.3% | 2 qtrs — |
| 65 | GEODE CAPITAL MANAGEMENT, LLC | 102.4K +437.0 (+0.4%) | 3.59M +692.0K (+23.9%) | 0.09% -0.005 pp | 0.00% +0.000 pp | USD16.51 +112.5% | 12 qtrs — |
| 66 | WALLEYE CAPITAL LLC | 96.3K +96.3K (+100.0%) | 3.38M +3.4M (+100.0%) | 0.08% +0.081 pp | 0.01% +0.010 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 67 | ALPS ADVISORS INC | 92.9K +92.9K (+100.0%) | 3.26M +3.3M (+100.0%) | 0.08% +0.078 pp | 0.02% +0.019 pp | USD35.08 +0.0% | 6 qtrs — |
| 68 | SWEDBANK AB | 90.9K +90.9K (+100.0%) | 3.19M +3.2M (+100.0%) | 0.08% +0.076 pp | 0.00% +0.003 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 69 | SWISS NATIONAL BANK | 88.9K +1.8K (+2.1%) | 3.12M +641.5K (+25.9%) | 0.07% -0.003 pp | 0.00% +0.000 pp | USD22.89 +53.3% | 7 qtrs — |
| 70 | JTC EMPLOYER SOLUTIONS TRUSTEE LTD | 75.5K +75.5K (+100.0%) | 3.02M +3.0M (+100.0%) | 0.06% +0.063 pp | 0.20% +0.205 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 71 | LEGATO CAPITAL MANAGEMENT LLC | 83.8K +60.5K (+258.7%) | 2.94M +2.3M (+342.5%) | 0.07% +0.050 pp | 0.25% +0.181 pp | USD30.91 +13.5% | 3 qtrs — |
| 72 | CENTIVA CAPITAL, LP | 80.0K +80.0K (+100.0%) | 2.81M +2.8M (+100.0%) | 0.07% +0.067 pp | 0.02% +0.023 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 73 | CAPTION MANAGEMENT, LLC | 75.0K -1.1M (-93.6%) | 2.63M -30.6M (-92.1%) | 0.06% -0.977 pp | 0.02% -0.241 pp | USD28.18 +24.5% | 5 qtrs — |
| 74 | STEMPOINT CAPITAL LP | 73.1K -77.5K (-51.4%) | 2.56M -1.7M (-40.1%) | 0.06% -0.072 pp | 0.44% -0.418 pp | USD19.73 +77.8% | 4 qtrs — |
| 75 | RUSSELL INVESTMENTS GROUP, LTD. | 71.3K +71.3K (+100.0%) | 2.50M +2.5M (+100.0%) | 0.06% +0.060 pp | 0.00% +0.003 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 76 | STATE STREET CORP | 68.5K +4.7K (+7.4%) | 2.40M +589.0K (+32.5%) | 0.06% +0.001 pp | 0.00% +0.000 pp | USD21.38 +64.1% | 7 qtrs — |
| 77 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 63.3K +63.3K (+100.0%) | 2.22M +2.2M (+100.0%) | 0.05% +0.053 pp | 0.00% +0.002 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 78 | — | 59.3K +59.3K (+100.0%) | 2.08M +2.1M (+100.0%) | 0.05% +0.050 pp | 0.00% +0.002 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 79 | MIZUHO MARKETS CAYMAN LP | 47.9K +47.9K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.04% +0.040 pp | 0.08% +0.085 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 80 | JAIN GLOBAL LLC | 47.6K +47.6K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.04% +0.040 pp | 0.01% +0.008 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 81 | FRED ALGER MANAGEMENT, LLC | 47.5K +6.3K (+15.2%) | 1.67M +494.0K (+42.1%) | 0.04% +0.003 pp | 0.01% +0.002 pp | USD28.05 +25.1% | 5 qtrs — |
| 82 | AQUATIC CAPITAL MANAGEMENT LLC | 46.0K +46.0K (+100.0%) | 1.61M +1.6M (+100.0%) | 0.04% +0.039 pp | 0.05% +0.046 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 83 | IKARIAN CAPITAL, LLC | 45.8K -61.0K (-57.1%) | 1.61M -1.4M (-47.1%) | 0.04% -0.056 pp | 0.13% -0.181 pp | USD18.11 +93.7% | 3 qtrs — |
| 84 | SEI INVESTMENTS CO | 41.0K +41.0K (+100.0%) | 1.44M +1.4M (+100.0%) | 0.03% +0.035 pp | 0.00% +0.001 pp | USD35.08 +0.0% | 1 qtrs NEW |
| 85 | LEGAL & GENERAL GROUP PLC | 41.0K -4.8K (-10.5%) | 1.44M +135.8K (+10.4%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD21.01 +67.0% | 7 qtrs — |
| 86 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 40.3K -7.6K (-15.8%) | 1.41M +51.7K (+3.8%) | 0.03% -0.009 pp | 0.00% +0.000 pp | USD19.51 +79.8% | 7 qtrs — |
| 87 | BELLEVUE GROUP AG | 36.3K +21.7K (+148.7%) | 1.27M +859.1K (+206.8%) | 0.03% +0.018 pp | 0.02% +0.016 pp | USD30.18 +16.2% | 6 qtrs — |
| 88 | HIGHVISTA STRATEGIES LLC | 35.6K +3.8K (+11.8%) | 1.25M +343.1K (+37.9%) | 0.03% +0.002 pp | 0.32% +0.100 pp | USD23.55 +49.0% | 3 qtrs — |
| 89 | BOOTHBAY FUND MANAGEMENT, LLC | 33.9K -6.8K (-16.7%) | 1.19M +32.0K (+2.8%) | 0.03% -0.008 pp | 0.02% +0.001 pp | USD21.91 +60.1% | 5 qtrs — |
| 90 | KNIGHTS OF COLUMBUS ASSET ADVISORS LLC | 32.5K -1.1K (-3.4%) | 1.14M +183.6K (+19.2%) | 0.03% -0.003 pp | 0.06% +0.010 pp | USD18.35 +91.2% | 3 qtrs — |
| 91 | VERITION FUND MANAGEMENT LLC | 32.4K +18.6K (+134.2%) | 1.14M +743.0K (+188.9%) | 0.03% +0.015 pp | 0.00% +0.003 pp | USD28.84 +21.6% | 4 qtrs — |
| 92 | NORTHERN TRUST CORP | 32.1K -1.2K (-3.5%) | 1.13M +180.3K (+19.0%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD24.54 +43.0% | 5 qtrs — |
| 93 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 31.6K +— (+0.0%) | 1.11M +209.8K (+23.3%) | 0.03% -0.002 pp | 0.06% +0.004 pp | USD28.44 +23.3% | 2 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.76
Neutral
Ratio by volume
0.81
Neutral
Buys
34
Sells
45
Shares acquired
2.24M
Shares disposed
2.78M
Cash buys
—
Cash sales
31.00
Net activity
-534,933
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | LANGE LOUIS G | Director | S-Sale | D | Ordinary Shares | 44,173 | 30.41 | 1.34M | 10,806 | D | ↗ |
| 2026-03-09 | LANGE LOUIS G | Director | X-InTheMoney | A | Ordinary Shares | 44,619 | 11.50 | 513.1K | 54,979 | D | ↗ |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | Director / Officer | M-Exempt | D | Option (right to buy) | 101,409 | 0.00 | — | 520,229 | I | ↗ |
| 2026-03-06 | LANGE LOUIS G | Director | S-Sale | D | Ordinary Shares | 28,186 | 29.41 | 829.0K | 0 | I | ↗ |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | Director / Officer | M-Exempt | D | Option (right to buy) | 94,124 | 0.00 | — | 621,638 | I | ↗ |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | Director / Officer | M-Exempt | D | Option (right to buy) | 104,467 | 0.00 | — | 715,762 | I | ↗ |
| 2026-03-02 | Davidson Michael H. | Director / Officer | M-Exempt | D | Option (right to buy) | 443,707 | 0.00 | — | 239,267 | D | ↗ |
| 2026-02-26 | Davidson Michael H. | Director / Officer | M-Exempt | D | Option (right to buy) | 183,332 | 0.00 | — | 682,974 | D | ↗ |
| 2026-02-25 | Davidson Michael H. | Director / Officer | M-Exempt | D | Option (right to buy) | 58,253 | 0.00 | — | 866,306 | D | ↗ |
| 2026-02-24 | Davidson Michael H. | Director / Officer | M-Exempt | D | Option (right to buy) | 64,708 | 0.00 | — | 924,559 | D | ↗ |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | Director / Officer | S-Sale | D | Ordinary Shares | 14,692 | 35.00 | 514.2K | 84,289 | D | ↗ |
| 2026-01-28 | Kooij Louise Frederika | Officer | M-Exempt | D | Option (right to buy) | 32,612 | 10.90 | 355.5K | 73,134 | D | ↗ |
| 2026-01-27 | Kooij Louise Frederika | Officer | M-Exempt | D | Option (right to buy) | 39,816 | 10.90 | 434.0K | 105,746 | D | ↗ |
| 2026-01-26 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 34,400 | 10.90 | 375.0K | 58,753 | D | ↗ |
| 2026-01-23 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 38,172 | 10.90 | 416.1K | 62,525 | D | ↗ |
| 2026-01-21 | Somaiya Mayur Ian | Officer | M-Exempt | A | Ordinary Shares | 39,784 | 9.26 | 368.4K | 98,166 | D | ↗ |
| 2026-01-20 | Somaiya Mayur Ian | Officer | S-Sale | D | Ordinary Shares | 900 | 30.64 | 27.6K | 117,698 | D | ↗ |
| 2026-01-07 | van der Kamp Hilde Johanna | Director | A-Award | A | Option (right to buy) | 15,300 | 35.45 | 542.4K | 15,300 | D | ↗ |
| 2026-01-07 | Somaiya Mayur Ian | Officer | A-Award | A | Option (right to buy) | 115,000 | 35.45 | 4.08M | 115,000 | D | ↗ |
| 2026-01-07 | Smither John W | Director | A-Award | A | Ordinary Shares | 3,400 | 0.00 | — | 10,360 | D | ↗ |
| 2026-01-07 | McKenna Mark C. | Director | A-Award | A | Ordinary Shares | 3,400 | 0.00 | — | 10,360 | D | ↗ |
| 2026-01-07 | Lewis William | Director | A-Award | A | Ordinary Shares | 3,400 | 0.00 | — | 10,360 | D | ↗ |
| 2026-01-07 | LANGE LOUIS G | Director | A-Award | A | Option (right to buy) | 15,300 | 35.45 | 542.4K | 15,300 | D | ↗ |
| 2026-01-07 | Kooij Louise Frederika | Officer | A-Award | A | Option (right to buy) | 53,500 | 35.45 | 1.90M | 53,500 | D | ↗ |
| 2026-01-07 | Kastelein Johannes Jacob Pieter | Director / Officer | A-Award | A | Option (right to buy) | 115,000 | 35.45 | 4.08M | 115,000 | D | ↗ |
| 2026-01-07 | Gulfo Adele M. | Director | A-Award | A | Ordinary Shares | 3,400 | 0.00 | — | 14,260 | D | ↗ |
| 2026-01-07 | Davidson Michael H. | Director / Officer | A-Award | A | Ordinary Shares | 81,000 | 0.00 | — | 459,859 | D | ↗ |
| 2026-01-05 | Somaiya Mayur Ian | Officer | S-Sale | D | Ordinary Shares | 5,118 | 33.25 | 170.2K | 32,882 | D | ↗ |
| 2026-01-05 | Kooij Louise Frederika | Officer | S-Sale | D | Ordinary Shares | 2,647 | 33.25 | 88.0K | 12,353 | D | ↗ |
| 2026-01-05 | Kastelein Johannes Jacob Pieter | Director / Officer | S-Sale | D | Ordinary Shares | 6,000 | 33.25 | 199.5K | 73,481 | D | ↗ |
| 2025-12-26 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 5,000 | 10.90 | 54.5K | 58,872 | D | ↗ |
| 2025-12-24 | Kooij Louise Frederika | Officer | S-Sale | D | Ordinary Shares | 26,011 | 35.68 | 928.1K | 15,000 | D | ↗ |
| 2025-12-23 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 75,117 | 10.00 | 751.2K | 90,117 | D | ↗ |
| 2025-09-15 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 660 | 23.70 | 15.6K | 3,028,524 | I | ↗ |
| 2025-09-09 | Kooij Louise Frederika | Officer | M-Exempt | D | Option (right to buy) | 150,000 | 10.00 | 1.50M | 280,015 | D | ↗ |
| 2025-09-08 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 1,260 | 24.99 | 31.5K | 3,027,864 | I | ↗ |
| 2025-09-03 | Kooij Louise Frederika | Officer | S-Sale | D | Ordinary Shares | 18,073 | 25.09 | 453.5K | 15,000 | D | ↗ |
| 2025-09-02 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 18,073 | 0.00 | — | 33,073 | D | ↗ |
| 2025-08-25 | Kooij Louise Frederika | Officer | S-Sale | D | Ordinary Shares | 8,269 | 24.86 | 205.6K | 15,000 | D | ↗ |
| 2025-08-22 | Kastelein Johannes Jacob Pieter | Director / Officer | S-Sale | D | Ordinary Shares | 42,342 | 25.08 | 1.06M | 76,960 | I | ↗ |
| 2025-08-21 | Kastelein Johannes Jacob Pieter | Director / Officer | S-Sale | D | Ordinary Shares | 50,000 | 24.29 | 1.21M | 119,302 | I | ↗ |
| 2025-08-11 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 471 | 23.98 | 11.3K | 3,026,604 | I | ↗ |
| 2025-07-16 | Kling Douglas F | Officer | S-Sale | D | Ordinary Shares | 51,043 | 21.10 | 1.08M | 44,000 | D | ↗ |
| 2025-07-15 | Kling Douglas F | Officer | S-Sale | D | Ordinary Shares | 44,025 | 21.38 | 941.3K | 47,544 | D | ↗ |
| 2025-06-25 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 1,260 | 18.26 | 23.0K | 3,026,133 | I | ↗ |
| 2025-06-24 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 2,520 | 18.43 | 46.5K | 3,024,873 | I | ↗ |
| 2025-06-16 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 8,584 | 19.50 | 167.4K | 3,022,153 | I | ↗ |
| 2025-06-16 | Kling Douglas F | Officer | M-Exempt | D | Option (right to buy) | 78,101 | 10.00 | 781.0K | 372,829 | D | ↗ |
| 2025-06-01 | Marino Michael F III | Officer | A-Award | A | Ordinary Shares | 55,000 | 0.00 | — | 55,000 | D | ↗ |
| 2025-06-01 | LANGE LOUIS G | Director | M-Exempt | D | Restricted Stock Unit | 68 | 0.00 | — | 0 | D | ↗ |
| 2025-05-27 | Marino Michael F III | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-15 | Kling Douglas F | Officer | M-Exempt | D | Option (right to buy) | 100,000 | 10.00 | 1.00M | 450,930 | D | ↗ |
| 2025-05-01 | LANGE LOUIS G | Director | M-Exempt | A | Ordinary Shares | 69 | 0.00 | — | 28,118 | I | ↗ |
| 2025-05-01 | Audet Juliette Berangere | Officer | A-Award | A | Option (right to buy) | 30,000 | 20.03 | 600.9K | 30,000 | D | ↗ |
| 2025-04-15 | Kling Douglas F | Officer | M-Exempt | D | Option (right to buy) | 100,000 | 10.00 | 1.00M | 550,930 | D | ↗ |
| 2025-04-15 | Gulfo Adele M. | Director | A-Award | A | Option (right to buy) | 50,700 | 16.06 | 814.2K | 50,700 | D | ↗ |
| 2025-04-14 | LANGE LOUIS G | Director | M-Exempt | A | Ordinary Shares | 69 | 0.00 | — | 28,049 | I | ↗ |
| 2025-03-26 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 1,135 | 22.49 | 25.5K | 3,013,569 | I | ↗ |
| 2025-03-26 | LANGE LOUIS G | Director | M-Exempt | D | Restricted Stock Unit | 3,102 | 0.00 | — | 206 | D | ↗ |
| 2025-03-26 | Kooij Louise Frederika | Officer | M-Exempt | D | Restricted Stock Unit | 8,269 | 0.00 | — | 0 | D | ↗ |
| 2025-03-26 | Kling Douglas F | Officer | A-Award | A | Restricted Stock Unit | 16,539 | 0.00 | — | 16,539 | D | ↗ |
| 2025-03-26 | Kastelein Johannes Jacob Pieter | Director / Officer | A-Award | A | Ordinary Shares | 19,302 | 0.00 | — | 169,302 | I | ↗ |
| 2025-03-26 | Davidson Michael H. | Director / Officer | M-Exempt | A | Ordinary Shares | 38,394 | 0.00 | — | 402,699 | D | ↗ |
| 2025-03-24 | Kastelein Johannes Jacob Pieter | Director / Officer | M-Exempt | D | Option (right to buy) | 150,000 | 0.00 | — | 820,229 | I | ↗ |
| 2025-03-17 | Kling Douglas F | Officer | M-Exempt | A | Ordinary Shares | 88,112 | 0.00 | — | 132,112 | D | ↗ |
| 2025-03-04 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 4,005 | 21.02 | 84.2K | 3,012,434 | I | ↗ |
| 2025-03-04 | Kooij Louise Frederika | Officer | M-Exempt | A | Ordinary Shares | 150,000 | 0.00 | — | 165,000 | D | ↗ |
| 2025-02-19 | Kling Douglas F | Officer | M-Exempt | A | Ordinary Shares | 9,218 | 0.00 | — | 53,218 | D | ↗ |
| 2025-02-18 | Kling Douglas F | Officer | S-Sale | D | Ordinary Shares | 90,782 | 19.54 | 1.77M | 44,000 | D | ↗ |
| 2025-01-30 | Kling Douglas F | Officer | M-Exempt | D | Option (right to buy) | 13,578 | 0.00 | — | 226,145 | D | ↗ |
| 2025-01-29 | Kling Douglas F | Officer | M-Exempt | D | Option (right to buy) | 56,863 | 0.00 | — | 239,723 | D | ↗ |
| 2025-01-28 | Somaiya Mayur Ian | Officer | S-Sale | D | Ordinary Shares | 11,495 | 20.93 | 240.6K | 41,405 | D | ↗ |
| 2025-01-28 | Kling Douglas F | Officer | S-Sale | D | Ordinary Shares | 5,148 | 21.93 | 112.9K | 44,000 | D | ↗ |
| 2025-01-27 | Somaiya Mayur Ian | Officer | S-Sale | D | Ordinary Shares | 33,679 | 22.38 | 753.7K | 51,304 | D | ↗ |
| 2025-01-27 | Kling Douglas F | Officer | S-Sale | D | Ordinary Shares | 80,359 | 22.46 | 1.80M | 67,815 | D | ↗ |
| 2025-01-07 | van der Kamp Hilde Johanna | Director | A-Award | A | Ordinary Shares | 6,960 | 0.00 | — | 6,960 | D | ↗ |
| 2025-01-07 | Somaiya Mayur Ian | Officer | A-Award | A | Ordinary Shares | 38,000 | 0.00 | — | 38,000 | D | ↗ |
| 2025-01-07 | Smither John W | Director | A-Award | A | Ordinary Shares | 6,960 | 0.00 | — | 6,960 | D | ↗ |
| 2025-01-07 | McKenna Mark C. | Director | A-Award | A | Ordinary Shares | 6,960 | 0.00 | — | 6,960 | D | ↗ |
| 2025-01-07 | Lewis William | Director | A-Award | A | Ordinary Shares | 6,960 | 0.00 | — | 6,960 | D | ↗ |
| 2025-01-07 | LANGE LOUIS G | Director | A-Award | A | Ordinary Shares | 6,960 | 0.00 | — | 6,960 | D | ↗ |
| 2025-01-07 | Kooij Louise Frederika | Officer | A-Award | A | Ordinary Shares | 15,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-01-07 | Kling Douglas F | Officer | A-Award | A | Ordinary Shares | 44,000 | 0.00 | — | 44,000 | D | ↗ |
| 2025-01-07 | Kastelein Johannes Jacob Pieter | Director / Officer | A-Award | A | Ordinary Shares | 34,000 | 0.00 | — | 34,000 | D | ↗ |
| 2025-01-07 | JONES WILLIAM A JR | Officer | A-Award | A | Ordinary Shares | 43,000 | 0.00 | — | 43,000 | D | ↗ |
| 2025-01-07 | Davidson Michael H. | Director / Officer | A-Award | A | Ordinary Shares | 123,529 | 0.00 | — | 123,529 | D | ↗ |
| 2025-01-07 | Audet Juliette Berangere | Officer | A-Award | A | Ordinary Shares | 14,000 | 0.00 | — | 15,104 | D | ↗ |
| 2025-01-06 | van der Kamp Hilde Johanna | Director | A-Award | A | Option (right to buy) | 32,500 | 25.85 | 840.1K | 32,500 | D | ↗ |
| 2025-01-06 | Smither John W | Director | A-Award | A | Option (right to buy) | 32,500 | 25.85 | 840.1K | 32,500 | D | ↗ |
| 2025-01-06 | McKenna Mark C. | Director | A-Award | A | Option (right to buy) | 32,500 | 25.85 | 840.1K | 32,500 | D | ↗ |
| 2025-01-06 | Lewis William | Director | A-Award | A | Option (right to buy) | 32,500 | 25.85 | 840.1K | 32,500 | D | ↗ |
| 2025-01-06 | LANGE LOUIS G | Director | A-Award | A | Option (right to buy) | 32,500 | 25.85 | 840.1K | 32,500 | D | ↗ |
| 2025-01-06 | Davidson Michael H. | Director / Officer | A-Award | A | Option (right to buy) | 670,467 | 25.85 | 17.33M | 670,467 | D | ↗ |
| 2025-01-02 | Somaiya Mayur Ian | Officer | A-Award | A | Option (right to buy) | 220,000 | 25.96 | 5.71M | 220,000 | D | ↗ |
| 2025-01-02 | Kooij Louise Frederika | Officer | A-Award | A | Option (right to buy) | 80,000 | 25.96 | 2.08M | 80,000 | D | ↗ |
| 2025-01-02 | Kling Douglas F | Officer | A-Award | A | Option (right to buy) | 250,000 | 25.96 | 6.49M | 250,000 | D | ↗ |
| 2025-01-02 | Kastelein Johannes Jacob Pieter | Director / Officer | A-Award | A | Option (right to buy) | 200,000 | 25.96 | 5.19M | 200,000 | D | ↗ |
| 2025-01-02 | JONES WILLIAM A JR | Officer | A-Award | A | Option (right to buy) | 200,000 | 25.96 | 5.19M | 200,000 | D | ↗ |
| 2025-01-02 | Audet Juliette Berangere | Officer | A-Award | A | Option (right to buy) | 100,000 | 25.96 | 2.60M | 100,000 | D | ↗ |
| 2024-12-30 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 29,846 | 25.54 | 762.2K | 10,656,172 | I | ↗ |
| 2024-12-27 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 41,472 | 25.95 | 1.08M | 10,686,018 | I | ↗ |
| 2024-12-26 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 33,438 | 26.01 | 869.6K | 10,727,490 | I | ↗ |
| 2024-12-24 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 16,164 | 25.66 | 414.8K | 10,760,928 | I | ↗ |
| 2024-12-23 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 25,132 | 25.49 | 640.6K | 10,777,092 | I | ↗ |
| 2024-12-20 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 44,143 | 25.53 | 1.13M | 10,807,853 | I | ↗ |
| 2024-12-19 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 56,506 | 25.45 | 1.44M | 10,851,996 | I | ↗ |
| 2024-12-18 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 54,518 | 25.72 | 1.40M | 10,954,712 | I | ↗ |
| 2024-12-17 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 66,648 | 25.60 | 1.71M | 11,056,966 | I | ↗ |
| 2024-12-16 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 1,096 | 25.00 | 27.4K | 11,123,614 | I | ↗ |
| 2024-12-13 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 25,751 | 25.01 | 644.0K | 11,124,710 | I | ↗ |
| 2024-12-13 | Bain Capital Life Sciences Investors, LLC | 10% Owner | P-Purchase | A | Pre-Funded Warrant (right to buy) | 1,632,653 | 0.00 | 163.27 | 1,632,653 | I | ↗ |
| 2024-12-12 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 140,048 | 25.25 | 3.54M | 11,176,424 | I | ↗ |
| 2024-12-11 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 130,561 | 25.26 | 3.30M | 11,339,949 | I | ↗ |
| 2024-12-10 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 259,739 | 25.22 | 6.55M | 11,519,021 | I | ↗ |
| 2024-11-18 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 33,273 | 25.08 | 834.4K | 11,778,760 | I | ↗ |
| 2024-11-15 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 8,530 | 25.02 | 213.4K | 11,812,033 | I | ↗ |
| 2024-11-14 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 9,832 | 25.01 | 245.9K | 11,820,563 | I | ↗ |
| 2024-11-13 | ForGrowth NAP B.V. | 10% Owner | S-Sale | D | Ordinary Shares | 1,066 | 25.00 | 26.7K | 11,830,395 | I | ↗ |
| 2024-10-09 | Davidson Michael H. | Director / Officer | G-Gift | D | Warrant (right to buy) | 15,000 | 11.50 | 172.5K | 85,000 | D | ↗ |
| 2024-10-01 | Kooij Louise Frederika | Officer | S-Sale | D | Ordinary Shares | 45,000 | 15.72 | 707.4K | 0 | D | ↗ |
| 2024-09-27 | Kooij Louise Frederika | Officer | M-Exempt | D | Option (right to buy) | 45,000 | 0.00 | — | 168,073 | D | ↗ |
| 2024-09-26 | Audet Juliette Berangere | Officer | P-Purchase | A | Ordinary Shares | 1,104 | 15.70 | 17.3K | 1,104 | D | ↗ |
| 2024-08-20 | Davidson Michael H. | Director / Officer | P-Purchase | A | Ordinary Shares | 5,000 | 16.27 | 81.4K | 209,784 | — | ↗ |
| 2024-07-17 | McKenna Mark C. | Director | A-Award | A | Option (right to buy) | 72,500 | 18.81 | 1.36M | 72,500 | — | ↗ |
| 2024-07-16 | McKenna Mark C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-16 | Joustra Wouter | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-20 | Davidson Michael H. | Director / Officer | P-Purchase | A | Ordinary Shares | 5,000 | 17.26 | 86.3K | 204,784 | — | ↗ |
| 2024-04-25 | JONES WILLIAM A JR | Officer | — | D | Option (right to buy) | 130,000 | 11.17 | 1.45M | 0 | — | ↗ |
| 2024-04-01 | Audet Juliette Berangere | Officer | A-Award | A | Option (right to buy) | 250,000 | 21.37 | 5.34M | 250,000 | — | ↗ |
| 2024-03-26 | Topper James N | Director | P-Purchase | A | Ordinary Shares | 8,429 | 21.50 | 181.2K | 3,008,429 | — | ↗ |
| 2024-03-26 | Kastelein Johannes Jacob Pieter | Director / Officer | S-Sale | D | Ordinary Shares | 190,476 | 21.50 | 4.10M | 0 | — | ↗ |
| 2024-02-13 | LANGE LOUIS G | Director | P-Purchase | A | Ordinary Shares | 5,000 | 19.00 | 95.0K | 24,878 | — | ↗ |
| 2024-01-04 | Lewis William | Director | A-Award | A | Option (right to buy) | 100,000 | 12.01 | 1.20M | 100,000 | — | ↗ |
| 2024-01-01 | van der Kamp Hilde Johanna | Director | A-Award | A | Option (right to buy) | 10,000 | 11.17 | 111.7K | 10,000 | — | ↗ |
| 2024-01-01 | Somaiya Mayur Ian | Officer | A-Award | A | Option (right to buy) | 80,000 | 11.17 | 893.6K | 80,000 | — | ↗ |
| 2024-01-01 | Smither John W | Director | A-Award | A | Option (right to buy) | 10,000 | 11.17 | 111.7K | 10,000 | — | ↗ |
| 2024-01-01 | LANGE LOUIS G | Director | A-Award | A | Option (right to buy) | 10,000 | 11.17 | 111.7K | 10,000 | — | ↗ |
| 2024-01-01 | Kooij Louise Frederika | Officer | A-Award | A | Option (right to buy) | 150,494 | 11.17 | 1.68M | 150,494 | — | ↗ |
| 2024-01-01 | Kling Douglas F | Officer | A-Award | A | Option (right to buy) | 323,771 | 11.17 | 3.62M | 323,771 | — | ↗ |
| 2024-01-01 | Kastelein Johannes Jacob Pieter | Director / Officer | A-Award | A | Option (right to buy) | 500,000 | 11.17 | 5.59M | 500,000 | — | ↗ |
| 2024-01-01 | ForGrowth NAP B.V. | 10% Owner | — | I | Ordinary Shares | 0 | 0.00 | — | 11,831,461 | — | ↗ |
| 2024-01-01 | Davidson Michael H. | Director / Officer | A-Award | A | Option (right to buy) | 1,039,939 | 11.17 | 11.62M | 1,039,939 | — | ↗ |
| 2023-12-29 | van der Kamp Hilde Johanna | Director | — | D | Option (right to buy) | 18,000 | 13.26 | 238.7K | 0 | — | ↗ |
| 2023-12-29 | Topper James N | Director | — | I | Ordinary Shares | 0 | 0.00 | — | 3,000,000 | — | ↗ |
| 2023-12-29 | Somaiya Mayur Ian | Officer | — | D | Option (right to buy) | 824,697 | 9.26 | 7.64M | 0 | — | ↗ |
| 2023-12-29 | Smither John W | Director | — | D | Option (right to buy) | 18,600 | 10.22 | 190.1K | 0 | — | ↗ |
| 2023-12-29 | Slootweg Hugo Alexander | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | LANGE LOUIS G | Director | — | D | Ordinary Shares | 0 | 0.00 | — | 9,878 | — | ↗ |
| 2023-12-29 | Kooij Louise Frederika | Officer | — | I | Option (right to buy) | 213,073 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | Kling Douglas F | Officer | — | D | Option (right to buy) | 283,213 | 10.90 | 3.09M | 0 | — | ↗ |
| 2023-12-29 | Kastelein Johannes Jacob Pieter | Director / Officer | — | I | Employee Option (right to buy) | 1,171,902 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | Downing Nicholas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | Davidson Michael H. | Director / Officer | — | D | Ordinary Shares | 0 | 0.00 | — | 199,784 | — | ↗ |
| 2023-12-29 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Ordinary Shares | 0 | 0.00 | — | 10,473,913 | — | ↗ |
| 2023-12-29 | Audet Juliette Berangere | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-23 | Topper James N | Director | — | I | Warrant (right to buy) | 333,333 | 11.50 | 3.83M | 0 | — | ↗ |
| 2022-12-22 | LANGE LOUIS G | Director | — | D | Warrant (right to buy) | 44,619 | 11.50 | 513.1K | 0 | — | ↗ |
| 2022-12-22 | Davidson Michael H. | Director / Officer | — | D | Warrant (right to buy) | 100,000 | 11.50 | 1.15M | 0 | — | ↗ |
| 2022-12-22 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Warrant (right to buy) | 100,000 | 11.50 | 1.15M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-24.3K
Shares Outstanding
114.98M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Michael Davidson, M.D. Chief Executive Officer | 621.3K | — | — | 5.35M | 497.0K | 3.9K | 6.47M | 82.65% | ↗ |
| 2 | 2024 | John Kastelein, M.D., Ph.D. FESC Chief Scientific Officer | 486.0K | — | — | 2.57M | 327.0K | — | 3.38M | 75.97% | ↗ |
| 3 | 2024 | Juliette Audet Chief Strategy and Business Officer | 322.3K | — | — | 2.60M | 188.4K | 25.1K | 3.14M | 82.93% | ↗ |
| 4 | 2024 | Douglas Kling Chief Operating Officer | 500.0K | — | — | 1.66M | 400.0K | 13.8K | 2.58M | 64.56% | ↗ |
| 5 | 2024 | Ian Somaiya Chief Financial Officer | 468.0K | — | — | 411.3K | 368.6K | 4.7K | 1.25M | 32.84% | ↗ |
| 6 | 2023 | Michael Davidson, M.D. Chief Executive Officer | 569.0K | 313.0K | — | 4.92M | — | — | 5.81M | 84.81% | ↗ |
| 7 | 2023 | Ian Somaiya Chief Financial Officer | 90.6K | 40.0K | — | 3.42M | — | — | 3.55M | 96.32% | ↗ |
| 8 | 2023 | John Kastelein, M.D., Ph.D. FESC Chief Scientific Officer | 459.3K | 218.4K | — | 2.30M | — | — | 2.98M | 77.25% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | 1M | — |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | 808.1K | — |
| Douglas F. Kling | Chief Operating Officer | 790.1K | male |
| Mayur Amrat Somaiya | Chief Financial Officer | 770.4K | male |
| Louise Kooij | Chief Accounting Officer | 695.4K | female |
| Juliette Audet | Chief Strategy & Business Officer | 653.0K | female |
| Marc Ditmarsch | Chief Development Officer | — | — |
| Bob Rambo | Executive Vice President of Marketing | — | male |
| Maryellen McQuade | Chief People Officer | — | female |
| Matthew Philippe | Executive Vice President &Head of Investor Relations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NAMS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
